ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC
The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.
Therapy Area
EMD Serono partners US government to widen IVF access
Oceanpine Capital to acquire 80% equity stake in Beijing Jacoray
Kailera nets $600m to power Phase III launch of obesity drug
CIPO grants patent to Palisade Bio’s PALI-2108
Flu vaccine uptake increases 28% in England
Novo Nordisk buys MASH specialist Akero for up to $5.2bn
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
